 |
Norovirus VLP Vaccines: LigoCyte’s norovirus vaccines have been developed using a virus-like particle (VLP) technology that mimics the surface configuration of the live virus without the ability to cause infection. The vaccines have been formulated for intranasal delivery to stimulate a robust mucosal and systemic immune response. LigoCyte has completed two Phase I safety studies where the vaccine was shown to be immunogenic and generally well tolerated. LigoCyte is currently conducting a Phase I/II proof-of-principle challenge study in healthy human adult volunteers. Read More
|
|
|
 |
RSV Vaccine: LigoCyte’s RSV vaccine program is based on the company’s unique virus-like-particle (VLP) technology that presents the RSV-F antigen, the protein that mediates cell entry, in its native form. LigoCyte’s RSV-F VLP vaccine candidate has achieved neutralizing and protective responses in both mouse and cotton rat models of infection.
|
|
|
|
Influenza VLP Vaccine
Seasonal: LigoCyte’s VLP technology is readily adaptable to creating VLP vaccines to protect against a number of infections caused by enveloped viruses such as influenza. Seasonal influenza vaccines, administered annually, contain antigens from three strains of influenza virus (influenza A/H1N1, A/H3N1, and influenza B). In preclinical experiments, a LigoCyte influenza VLP vaccine representing only the H1N1 strain provided protection against lethal levels of infection by not only the A/H1N1 strain, but also against the A/H3N2 strain. Remarkably, the H1N1 VLP vaccine also protected against lethal levels of infection by the most dangerous of the avian influenza strains, A/H5N1. This degree of “cross protection” is not typically associated with influenza vaccines, which is one of the reasons that annual immunizations are required to protect against subtle changes in the virus from year to year.
Pandemic: In addition to the need for a better seasonal influenza vaccine, there is a significant need for a vaccine that offers protection against the strains of “avian influenza” that are currently circulating throughout the world. These emerging avian influenza viruses have caused global conern as a potential pandemic threat. The cross-protective properties of LigoCyte’s influenza VLP vaccines are ideally suited to protect against strains of influenza that are yet to be identified, such as those associated with a future pandemic. In a virus challenge model, LigoCyte’s avian influenza VLP vaccine has demonstrated protection against multiple strains of avian influenza, a characteristic that is highly desirable in a vaccine that would be stockpiled by governments and provided to the public in the case of an pandemic. Read More
|
| |
|
| |
